Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost

American Journal of Managed Care

Volumn 10, Issue 7 II, 2004, Pages 493-500

  Zuckerman, Ilene H ^a   Weiss, Sheila R ^a   McNally, Diane ^a   Layne, Barbara ^b   Mullins, C Daniel ^a   Wang, Junling ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Pennsylvania Medical Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG USE; DRUG UTILIZATION; EDUCATION; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGED; DRUG COSTS; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MEDICAID; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT EDUCATION; PENNSYLVANIA; UNITED STATES;

EID: 3242812802     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, I: treatments following myocardial infarction. JAMA. 1988;260:2088-2093.
2. Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol. 1985;5:1428-1437.
3. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, II: morbidity results. JAMA. 1983;250:2814-2819.
4. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infanction, I: mortality results. JAMA. 1982;247:1707-1714.
5. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823-827.
6. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
7. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study. BMJ. 1975;3(5986):735-740.
8. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
9. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509-1514.
10. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol. 1995;26:1432-1436.
11. Chen I, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Do "America's Best Hospitals" perform better for acute myocardial infarction? N Engl J Med. 1999;340:286-292.
12. Woods KL, Kelley D, Lowy A, et al. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. The European Secondary Prevention Study Group. Eur Heart J. 1998;19:74-79.
13. Kizer IR, Cannon CP, McCabe CH, et al. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. Am Heart J. 1999;137:79-92.
14. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med. 1998;158:1901-1906.
15. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623-629.
16. Avanzini F, Zuanetti G, Latini R, et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? CISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators. Eur Heart J. 1997;18:1447-1456.
17. Fishkind D, Paris BE, Aronow WS. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1997;45:809-812.
18. Mendelson G, Aronow WS. Underutilization of beta-blockers in older patients with prior myocardial infarction or coronary artery disease in an academic, hospital-based geriatrics practice. J Am Geriatr Soc. 1997;45:1360-1361.
19. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799-805.
20. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med. 1994;9:599-605.
21. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med. 1992;93:605-610.
22. Phillips BG, Yim JM, Brown EJ, Jr, et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J. 1996;131:872-878.
23. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries. A profile at state and national levels. JAMA. 2000;284:1670-1676.
24. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 2003;289:305-312.
25. Butler J, Argobast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-1595.
26. Axtell SS, Ludwig E, Lope-Candales P. Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction. Clin Cardiol. 2001;24:114-118.
27. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269-1276.
28. Bradley EH, Holmboe ES, Mattera JA, et al. A qualitative study of increasing beta-blocker use after myocardial infarction: why do some hospitals succeed? JAMA. 2001;285:2604-2611.
29. Bradley EH, Holmboe ES, Wang Y, et al. What are hospitals doing to increase beta-blocker use? Jt Comm J Qual Saf. 2003;29(8):409-415.
30. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542-545.
31. Mitra S, Findley K, Frohnapple D, Mehta JL. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clin Cardiol. 2002;25:16-18.
32. Bradford WD, Chen J, Krumholz HM. Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics. 1999;15:257-268.
33. Soumerai SB, McLaughlin T, Spiegelman D, et al. Adverse outcomes of under-use of β-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-121.
34. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988;319:152-157.
35. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased β-blocker use following myocardial infarction. JAMA. 2000;284:2748-2754.
36. Heller DA, Ahern FM, Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J. 2000;140:663-671.
37. Treeage Software, Inc. August 15, 2003. Available at: http://www.treeage.com/. Accessed October 7, 2003.
38. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998:81:1110-1115.
39. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation. 1996;94:629-635.
40. National Committee for Quality Assurance. The Health Plan Employer Data and Information Set (HEDIS®). Available at: http://www.ncqa.org/Programs/ HEDIS/index.htm. Accessed October 7, 2003.
41. Kuntz KM, Lee TH. Cost-effectiveness of accepted measures for intervention in coronary heart disease. Coron Artery Dis. 1995:6:472-478.